Completed PHASE2 INTERVENTIONAL NCT00029393

Induction of Stable Chimerism for Sickle Cell Anemia

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Conditions Anemia, Sickle Cell Blood Disease Hematopoietic Stem Cell Transplantation

Interventions Hematopoietic Stem Cell Transplantation Immunosuppression

Updated 5 times since 2017 Last updated: Jul 28, 2016 Started: Aug 31, 2001 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00029393, this PHASE2 trial focuses on Anemia, Sickle Cell and Blood Disease and remains completed. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)

Data source: National Heart, Lung, and Blood Institute (NHLBI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.